Title Page

Corticosteroids and mortality in patients with severe Covid-19 who have autoantibodies

Zhu Cui, MD MPH *¹, Maxwell Roth, BS*², Yelena Averbukh, MD³, Andrei Assa, MD³, Azal Al Ani, MD⁴, William Southern, MD MS³, Morayma Reyes Gil MD PhD⁴, Shitij Arora, MD³

* Both authors contributed equally to this work

1. Division of General Internal Medicine, Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine
2. Albert Einstein College of Medicine
3. Division of Hospital Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine
4. Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine

Corresponding Author

Shitij Arora, MD

111 East 210th Street, NW651, Bronx, NY 10467

sharora@montefiore.org

There is no conflict of interest to declare.

Co Corresponding Author

Morayma Reyes Gil MD PhD

111 East 210th Street, Central Building, Room 301, Bronx, NY 10467

mreyesgi@montefiore.org

There is no conflict of interest to declare.

Abstract

Auto-reactivity in COVID-19 is increasingly being recognized and may identify a group of patients with inflammation severe enough to result in loss of self-tolerance. Corticosteroids are potent anti-inflammatory agents and now the standard of care for patients with severe Covid-19 requiring oxygen support/mechanical ventilation. We studied the outcomes of COVID-19 patients who demonstrated clinically identifiable auto-reactivity and received corticosteroid treatment.

In this retrospective cohort study, we included 51 COVID-19 patients admitted between March 10, 2020 and May 2, 2020 who received corticosteroid treatment and also had serum sample in our institution bio-bank available for ANA and RF ELISA. Twelve patients (23.5%) had positive ANA or RF. Mortality rate among patients with positive autoantibodies was significantly higher than those without (9/12 or 75% versus 13/39 or 33.3%, $p = 0.02$). The high mortality rate in patients with auto-reactivity warrants further investigation and may be the subgroup where additional immunomodulation is effective.

Introduction

Auto-reactivity in Coronavirus disease 2019 (COVID-19) is increasingly being recognized (1-3). Some of these autoantibodies may contribute to the development of severe disease or even long COVID symptoms that persist months after initial infection(3, 4). Autoantibodies are more commonly detected among patients with worse disease severity and higher CRP level (1, 2). They may identify a group of patients with inflammation severe enough to result in loss of self-tolerance(5). Corticosteroids are potent anti-inflammatory agents and now the standard of care for patients with severe Covid-19 requiring oxygen support/mechanical ventilation (6). We sought to study the outcomes of COVID-19 patients who demonstrated clinically identifiable auto-reactivity and received corticosteroid treatment.

Methods

We identified adult patients hospitalized with severe COVID-19 between March 10, 2020 and May 2, 2020, who were initiated on corticosteroids within 48 hours of admission, and received at least two doses of treatment (0.5mg/kg/day prednisone equivalent or higher). Patients who passed away within 48 hours of admission were excluded (Figure 1). Serum samples collected during hospitalization were promptly aliquoted and stored at -80°C. Antinuclear antibody (ANA) and rheumatoid factor (RF) testing were conducted using EliA kits on the Phadia 250 instrument following the manufacturer's instructions. Reporting units and cut-offs for determining a positive result were pre-specified by the manufacturer (see detailed methods in the supplementary file).

Results

Serum samples were available for 51 patients, 12 (23.5%) were positive for either ANA or RF (six ANA positive, six RF positive), and 39 (76.5%) were negative for both (three patients with equivocal results were categorized as negative for analysis). Three patients with positive autoantibodies had previously diagnosed autoimmune disease and one of whom with known positive RF prior to COVID-19 infection. Patients with autoantibodies had higher Charlson Comorbidity Index, but similar admission lymphocyte counts, C-reactive protein, and D-dimer levels (Table 1). There were a total of 22 deaths (43%). Among the 12 patients with positive ANA/RF, nine died (75%), whereas out of the 39 patients who were ANA/RF negative, thirteen died (33%). The mortality difference was statistically significant ($p=0.02$). Rate of mechanical ventilation was also higher among autoantibody-positive patients but not statistically significant (41.7% versus 28.2%, $p=0.48$).

Discussion

We report presence of autoantibodies among patients with severe COVID-19. Mortality rate was significantly higher among those with positive autoantibodies than those without. These findings are hypothesis generating. It may be possible that presence of autoantibodies reflects a state of hyper-inflammation where synergistic immunomodulation with corticosteroids and other targeted therapies (antagonists of interleukin-1 or interleukin-6) is more effective. Our study is limited by its small sample size, retrospective methodology, and types of autoimmune

antibody tested. We were also unable to differentiate between pre-existing autoantibodies and those with 'de-novo' autoantibody production due to severe Covid-19. Nonetheless, the high mortality rate in patients with auto-reactivity warrants further investigation.

References

1. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, et al. Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv : the preprint server for health sciences. 2020.
2. Woodruff MC, Ramonell RP, Lee FE-H, Sanz I. Clinically identifiable autoreactivity is common in severe SARS-CoV-2 Infection. medRxiv : the preprint server for health sciences. 2020:2020.10.21.20216192.
3. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).
4. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28-33.
5. Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3).
6. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

Table 1. Patient baseline characteristics, clinical characteristics on admission, treatments received, and clinical outcomes			
	ANA/RF Neg (N=39)	ANA/RF Pos (N= 12)	P Value
<i>Baseline Characteristics</i>			
Median Hospital Day of Sample Collection (IQR)	4 (2 – 8)	5 (1 – 7.5)	0.98
Median Age (IQR)	64 (47 – 77)	70 (59.5 – 83.5)	0.17
Female (%)	19 (48.7)	4 (33.3)	0.51
Autoimmune Disease (%)	0 (0)	3 (25.0)	0.01
Prior ANA/RF (%)			0.23
Positive	0 (0)	1 (8.3)	
Negative	2 (5.1)	1 (8.3)	
Unknown	37 (94.9)	10 (83.3)	
Ever Smoker (%)	1 (2.6)	2 (16.7)	0.13
Diabetes (%)	14 (35.9)	5 (41.7)	0.74
Median Charlson Comorbidity Index (IQR)	3 (1 – 3)	4 (2 – 7)	0.04
Full Code (%)	33 (84.6)	9 (75.0)	0.42
<i>Clinical Characteristics On Admission</i>			
Median Initial White Blood Cell Count (IQR), k/mcL	8.4 (6.8 – 10.8)	7.0 (5.4 – 12.6)	0.50
Median Initial Neutrophil Count (IQR), k/mcL	6.9 (5.6 – 9.1)	6.2 (3.9 – 10.9)	0.60
Median Initial Lymphocyte Count (IQR), k/mcL	0.9 (0.6 – 1.2)	0.75 (0.6 – 0.9)	0.12
Median Initial Creatinine (IQR), mg/dL	1.2 (0.8 – 1.9)	1.3 (1.0 – 2.4)	0.58
Median Initial Troponin (IQR), ng/mL	0.01 (0.01 – 0.04)	0.02 (0.01 – 0.06)	0.4
Median Initial CRP (IQR), mg/dL	15.8 (8.5 – 18.5)	17.6 (15.0 – 33.7)	0.17
Median Initial D-dimer (IQR) ug/mL	1.8 (0.8 – 3.7)	2.7 (1.1 – 5.9)	0.14
Median Initial IL6 (IQR), pg/mL	36.3 (10.4 – 126.6)	145.0 (17.3 – 272.3)	0.10
<i>Treatments Received</i>			
Hydroxychloroquine (%)	31 (79.5)	7 (58.3)	0.29
Sarilumab or Leronlimab (%)	2 (5.1)	4 (33.3)	0.02
Remdesivir (%)	5 (12.8)	1 (8.3)	1
<i>Clinical Outcomes</i>			
Highest O2 Requirement			

(%):			
RA/NC	12 (30.8)	1 (8.3)	0.15
NRB	11 (28.2)	5 (41.7)	0.48
HFNC/CPAP/BiPAP	5 (12.8)	1 (8.3)	1
MV	11 (28.2)	5 (41.7)	0.48
Median Hospital stay (IQR)	7 (5 -11)	9 (4.5 -13)	0.80
Death (%)	13 (33.3)	9 (75.0)	0.02

Retrospective cohort study
Montefiore Medical Center
The Bronx, New York

Adult patients hospitalized with COVID-19
who received ≥ 2 doses of
0.5 mg/kg/day prednisone
equivalent or higher
n=325

Patients crossmatched
against plasma or serum
samples previously
stored in hospital
biobank for research
total samples = 3672

Available plasma or
serum patient samples
(median collection time:
hospital day 4)
n=51

Autoimmunity
Assays

Antinuclear
Antibody IgG

Rheumatoid
Factor IgM

%Death
 $p = 0.02$

ANA/RF Positive
n = 12

ANA/RF Negative
n = 39